IMMUNIC, INC. (IMUX): Nasdaq/NYSE listing notice — Immunic transfers to Nasdaq Capital Market after bid price non-compliance; extended grace until June 22, 2026

IMMUNIC, INC.

Received approval on Jan 5, 2026 to transfer listing from Nasdaq Global Select to Capital Market, effective Jan 7, 2026.
Failed to regain compliance with $1.00 minimum bid price rule by Dec 24, 2025 deadline.
Transfer grants additional 180-day grace period until June 22, 2026 to meet bid price rule.
Company notified Nasdaq it will seek reverse stock split if needed to regain compliance.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

IMMUNIC, INC. received a nasdaq extension granted notice regarding minimum bid price (rules 5450(a)(1)).

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price
Rules: 5450(a)(1)

Exact text from the filing

al Select Market, and listed companies must meet certain financial requirements and comply with Nasdaq’s corporate governance requirements. As previously disclosed, on June 27, 2025, the Company received a letter from Nasdaq indicating that the Company was not in compliance with Nasdaq Listing Rule 5450(a)(1) because the closing bid price per share for the Company’s common stock had closed below $1.00 for the previous 30 consecutive business days (the “Bid Price Rule”). The Company was given a 180-day grace period, until December 24, 2025, to regain compliance with the rule. The Company had no

View on SEC.gov

Browse all listing & compliance notices →

IMMUNIC, INC. filing history →

Source: SEC EDGAR

accession 0001193805-26-000011

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.